Investors

LINE Investors Unite: Join Schall Law Firm in Pursuing Lineage, Inc. Securities Fraud Claims

by

Investors in LINE have the opportunity to participate in a securities fraud lawsuit against Lineage, Inc., led by the Schall Law Firm. This legal action follows allegations that the company may have misrepresented critical information regarding its business practices and financial health, which could have significant implications for shareholders. Lineage, Inc., a biotechnology firm primarily focused on developing innovative therapies, has recently come under scrutiny. The company’s stock has been affected by disclosures that suggest potential discrepancies in their reported data. Investors believe these omissions could have had a material impact on their investment decisions … Read more

RBGLY Investors Urged to Step Forward in Class-Action Lawsuit Against Reckitt Benckiser Group Over Alleged Securities Fraud

by

Investors in Reckitt Benckiser Group PLC are presented with the opportunity to take a leading role in a securities fraud lawsuit against the British multinational consumer goods company. Based in Slough, England, Reckitt Benckiser has come under scrutiny as concerns mount over alleged misleading statements to investors regarding its financial performance. The controversy revolves around potential inaccuracies in the company’s reporting and the implications of those figures on investor decisions. Legal experts note that shareholders can significantly influence the direction of the lawsuit by joining together in this action against the company. The outcome could … Read more

Oppenheimer Holdings Ventures into Litigation Funding, Seeking New Opportunities for Institutional Investors

by

New York, New York – Oppenheimer Holdings is making strides into the litigation funding sector, expanding its reach in a growing financial industry. In March, Ron Ryder, who serves as co-head of special assets trading at the firm, communicated the firm’s intent to represent institutional investors. They aim to provide funding to law firms or acquire a portion of attorneys’ contingency fees, signaling a strategic move into a lucrative market. Litigation funding has gained traction in recent years, with various investors drawn to the potential for significant returns. By backing legal cases, these investors can … Read more

Rocket Pharmaceuticals Investors Urged to Join Class Action Ahead of August 11 Deadline, Claims of Misleading Trial Data Surface

by

NEW YORK — Investors who purchased shares of Rocket Pharmaceuticals, Inc. between February 27 and May 26, 2025, are being reminded of an upcoming deadline related to a class action lawsuit. The Rosen Law Firm, a prominent global investor rights law firm, has announced that August 11, 2025, is the last day to apply as a lead plaintiff in this case. Those who bought securities of Rocket Pharmaceuticals during the specified period may be eligible for compensation without any upfront costs. Prospective participants can contact Phillip Kim, a legal representative from Rosen Law Firm, for … Read more